VERICEL CORPORATION Preferred Stock, Value, Outstanding
VERICEL CORPORATION (VCEL) had Preferred Stock, Value, Outstanding of $38.39 million as of 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockValueOutstanding · last filed 2016-05-10
- 2016-03-31: Preferred Stock, Value, Outstanding $38.39M.
- 2015-12-31: Preferred Stock, Value, Outstanding $38.39M.
- 2015-09-30: Preferred Stock, Value, Outstanding $38.39M.
- 2015-06-30: Preferred Stock, Value, Outstanding $38.39M.
| Period end | Preferred Stock, Value, Outstanding |
|---|---|
| 2016-03-31 | $38.39M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $38.39M 10-Q · filed 2016-05-10 |
| 2015-09-30 | $38.39M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $38.39M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $38.39M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $38.39M 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |